Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics (PD)/treatment response biomarkers.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04856982
Study type Interventional
Source Biogen
Contact US Biogen Clinical Trial Center
Phone 866-633-4636
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date May 7, 2021
Completion date August 7, 2027